Introduction: Cervical cancer is the fourth most common and accounts for about 6.6% of all cancers in women. Aim: The aim was to determine the frequency of premalignant and malignant changes in the cervix, to examine the histological-cytological correlation of premalignant and malignant changes in the cervix and the correlation of the women's age with the stage of cervical disease. Material and Methods: A retrospective study analyzed 186 cervical biopsy specimens and cervical smears (Papanicolau test) at the Institute of Pathology of the Faculty of Medicine in Pristina, based in Kosovska Mitrovica, over a three-year period from 2016 to 2018. Results: Of the 186 subjects, 62 had mild premalignant changes of type LSIL, 22 HSIL, and as many as 20 (10.75%) cervical cancer. There was a statistically significant positive association between histological and cytological findings (r = 0.854; p <0.001). There was a statistically significant difference in the age of the subjects with regard to histological findings (F = 11,327; p <0.001). Subjects with HSIL were significantly older than those diagnosed with cervicitis chronica (p = 0.029). Subjects diagnosed with planocellular carcinoma were significantly older than women with cervicitis chronica (p <0.001) and LSIL (p <0.001). Conclusion: There is an increasing trend of cervical cancer in Northern Kosovo and in the Serbian enclaves in central Kosovo and Metohija. Subjects with cervical cancer were significantly older than subjects with mild premalignant cervical changes. There is a significant histologic-cytological correlation of cervical findings, so we believe that more massive cervical screening, especially in younger women, could reduce the incidence of premalignant and malignant diseases of the cervix.
References
1.
Vukicevic D, Mitic R, Mijovic M, Mitic N, Vitkovic L, Djerkovic B, et al. The descriptive and epidemiological characteristics of cervical cancer. Praxis medica. 2015;44(1):67–72.
2.
The Bethesda System for Reporting Cervical Cytology. 2004.
3.
Wei Q, Fu B, Liu J, Xu J, Zhao T. Combined detection of p16INK4a and IMP3 increase the concordance rate between cervical cytologic and histologic diagnosis. 2013;6(8):1549–57.
4.
Berek BJS, Gynecology N. 2007.
5.
Gajanin Z, Vilendecic R, Ecim-Zlojutro V, Gajanin R, Budakov P. Significance of immunohistochemical expression of p16INK4a in the differentiation of inflammatory and preneoplastic cervical lesions. Srpski arhiv za celokupno lekarstvo. 2015;143(1–2):42–9.
6.
Correlation of Cervical Pap Smear with Biopsy in the Lesion of Cervix. 2016;3.
7.
Krishnan K, Thomas A. Correlation of cervical cytology with high‐risk <scp>HPV</scp> molecular diagnosis, genotypes, and histopathology—A four year study from the <scp>UAE</scp>. Diagnostic Cytopathology. 2016;44(2):91–7.
8.
Vukićević D. Patologija grlića materice. Papir centar - Ranđelović Niš. 2014.
9.
National Cancer Institute workshop. 1989;262:931–4.
10.
Solomon D. The 2001 Bethesda System<SUBTITLE>Terminology for Reporting Results of Cervical Cytology</SUBTITLE> JAMA. 2002;287(16):2114.
11.
Vitkovic L, Perisic Z, Zamurovic M, Mitic N, Piperski V, Trajkovic G, et al. P16INK4a as an adjunct test in cervical cytology. 2015;36(6):685–9.
12.
Vitković L, B.N M, Perišić Ž, Piperski V, Trajković G, Anđelković Z, et al. Ekspresija proteina p16INK4a u normalnom i displastično promenjenom epitelu grlića materice. Naučni časopis Medicinskog fakulteta i Društva lekara Kosova i Metohije SLD. 2011;39(3–4):13–7.
13.
Pop-Trajović Z. Citološka slika cervikalnih intraepitelnih neoplazija. U: Stanimirović B (urednik) Dijagnostika i lečenje oboljenja cerviksa, vagine i vulve. 2006.
14.
Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, et al. Accuracy of the Papanicolaou Test in Screening for and Follow-up of Cervical Cytologic Abnormalities. Annals of Internal Medicine. 2000;132(10):810.
15.
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today. 2018;
16.
Solomon D. The 1988 Bethesda system for reporting cervical/vaginal citologic diagnoses. 1989;33:567–74.
17.
Vukićević D, Vančetović-Mijović M, Đerković B, Vitković L, Plešinac V. Humani papiloma virusi (HPV) i njihova uloga u nastanku prekanceroznih lezija i karcinoma grlića materice. 2011;39(3–4):115–9.
18.
Schiffman M, Doorbar J, Wentzensen N, de Sanjosé S, Fakhry C, Monk BJ, et al. Carcinogenic human papillomavirus infection. Nature Reviews Disease Primers. 2(1).
19.
Stanimirović B, Atanacković J, Babić M, Berisavac M, Bošković V, sar VT. Dijagnostika i lečenje oboljenja cerviksa, vagine i vulve. 2006.
20.
Vitković L, Perišić Ž, Trajković G, Mijović M, Savić S, Leštarević S, et al. Distribution of high-risk types of human papillomavirus compared to histopathological findings in cervical biopsies in women. Praxis medica. 2015;44(4):39–44.
21.
Koutsky L. Epidemiology of genital human papillomavirus infection. 1997;102:3–8.
22.
Villiers E-M, C F, TR B, H-U B, Hausen H. Classification of papillomaviruses. 2004;324:17–27.
23.
Vitkovic L, Mijovic M, Vukicevic D, Djerkovic B, Mitic N, Ilic A, et al. Histological-cytological reports correlation and reliability of papanicolau test for the detection of malignant changes in the cervix. Praxis medica. 2015;44(1):23–31.
24.
I.A.R.C. IARC Handbooks of Cancer Research Prevention. 2005;10.
25.
Okunade KS. Human papillomavirus and cervical cancer. 2019;
26.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018;68(6):394–424.
27.
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer. 2019;144(8):1941–53.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.